Last mentioned: Mar 21, 2026
Across the most recent 2 stories covering Missouri — 50% negative, 50% neutral sentiment, averaging 6.5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Public Notification
Official announcement made to the public and healthcare providers regarding state status.
Initial Diagnosis
Missouri DHSS confirms two positive test results for mpox.
Contact Tracing Launch
Public health officials begin identifying close contacts of the two patients.
Missouri Pause Request
DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
Hawley Federal Bill
Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
Louisiana Pause Request
DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
Missouri Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.
The Missouri Department of Health and Senior Services has confirmed the state's first two cases of mpox (monkeypox), marking the virus's official entry into the state. Health officials have launched immediate contact tracing efforts to contain potential community spread and are coordinating with federal partners for vaccine distribution.
The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
This page surfaces every story mentioning Missouri across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Missouri was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |